2025 Quality Assurance Reporting Requirements (QARR)

August 22, 2025

RE: Clarification #3 for Measurement Year (MY)
2025 Updates

Dear Colleague,

This letter contains information about the MY2025 Technical Specifications, the NYS MY2025 QARR List of Required Measures (Table1), and the MY2025 PLD File Specifications (PDF) . The files are posted on our Managed Care Information for Health Plans page. The revised specifications should be used in the plans' processing for MY2025 QARR.

This clarification includes the following changes made to the MY2025 QARR reporting requirements.

Change Version Version Date Section(s) Changed Change Summary
3 8/22/25 QARR MY2025
Technical Specifications
  1. NYS Measure - Continued Engagement in Substance Use Disorder (SUD) Treatment (CET) specifications have been updated MAT dispensing guidelines.
  2. NYS Measure - Use of Pharmacotherapy for Alcohol Use or Dependence (POA) - denominator specifications have been updated.
MY2025 Table 1: QARR List of Required Measures
  1. Annual Monitoring for Persons on Long-Term Opioid Therapy (AMO) and International Normalized Ratio Monitoring for Individuals on Warfarin (INR) - removed as a reporting requirement for Qualified Health Plans (QHP)
Patient-Level Detail File (PLD) MY2025 Commercial Line of Business:
  1. Social Need Screening and Intervention (SNS-E) Updated measurement period to January 1-December 31 to align with HEDIS specifications.
Medicaid Line of Business:
  1. Development Screening (DEV-N) and Documented Assessment After Mammogram (DBM-E) - Rows 237- 241 labels and field definitions updated to match measure short name and description. Remaining numbering has been updated accordingly.
  2. Social Need Screening and Intervention (SNS-E) Updated measurement period to January 1-December 31 to align with HEDIS specifications.
Exchange/Marketplace Line of Business:
  1. Childhood Immunization Status Electronic (CIS-E) and Colorectal Cancer Screening (COL-E) - Rows 159-162 labels and field definitions updated to match measure short name and description. Remaining numbering has been updated accordingly.
  2. Annual Monitoring for Persons on Long-Term Opioid Therapy (AMO) and International Normalized Ratio Monitoring for Individuals on Warfarin (INR) - Removed as a reporting requirement for Qualified Health Plans (QHP). Remaining numbering has been updated accordingly.
  3. Social Need Screening and Intervention (SNS-E) Updated measurement period to January 1-December 31 to align with HEDIS specifications.

If there are any questions about the above edits, or if you find issues or have concerns with the MY2025 Technical Specifications manual or other documents, please email nysqarr@health.ny.gov.

Sincerely,

Paloma Luisi, MPH
Director, Bureau of Quality Measurement & Evaluation
Center for Applied Research and Evaluation
Office of Health Services Quality and Analytics

CC:  R. Josberger
        E. Nichols
        C. Fan